Favorable response to second-line atezolizumab and bevacizumab following progression on nivolumab in advanced hepatocellular carcinoma

Second Line

Feasibility and benefits of systemic second-line therapy in advanced hepatocellular carcinoma (HCC) – a retrospective analysis

Zeitschrift für Gastroenterologie ◽

10.1055/s-0033-1360896 ◽

2014 ◽

Vol 52 (01) ◽

Author(s):

S Koch ◽

A Weinmann ◽

JU Marquardt ◽

PR Galle ◽

MA Wörns

Keyword(s):

Retrospective Analysis ◽

Second Line ◽

Second Line Therapy ◽

Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(15)00050-9 ◽

2015 ◽

Vol 16 (7) ◽

pp. 859-870 ◽

Cited By ~ 344

Author(s):

Andrew X Zhu ◽

Joon Oh Park ◽

Baek-Yeol Ryoo ◽

Chia-Jui Yen ◽

Ronnie Poon ◽

...

Keyword(s):

Line Treatment ◽

Second Line ◽

First Line ◽

Phase 3 ◽

Double Blind ◽

Multicentre Phase ◽

First Line Therapy ◽

Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first-line sorafenib: Patient reported outcome results across two phase III studies (REACH-2 and REACH)

Annals of Oncology ◽

10.1093/annonc/mdy282.006 ◽

2018 ◽

Vol 29 ◽

pp. viii208 ◽

Cited By ~ 4

Author(s):

A.X. Zhu ◽

R.S. Finn ◽

P.R. Galle ◽

J.M. Llovet ◽

J.F. Blanc ◽

...

Keyword(s):

Patient Reported Outcome ◽

Phase Iii ◽

Line Treatment ◽

Second Line ◽

First Line ◽

Two Phase ◽

Patient Reported ◽

Phase Iii Studies

Corrigendum to ‘Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study’ [Eur J Canc 81 (2017) 17–25]

European Journal of Cancer ◽

10.1016/j.ejca.2018.06.002 ◽

2018 ◽

Vol 100 ◽

pp. 135-136

Author(s):

Ian Chau ◽

Markus Peck-Radosavljevic ◽

Christophe Borg ◽

Peter Malfertheiner ◽

Jean Francois Seitz ◽

...

Keyword(s):

Phase Iii ◽

Line Treatment ◽

Second Line ◽

First Line ◽

First Line Therapy ◽

Eligibility for Second-line Therapy in Patients With Advanced Hepatocellular Carcinoma

American Journal of Clinical Oncology ◽

10.1097/coc.0000000000000754 ◽

2020 ◽

Vol Publish Ahead of Print ◽

Author(s):

Erica S. Tsang ◽

Janine M. Davies ◽

Jonathan M. Loree ◽

Howard J. Lim ◽

Daniel J. Renouf ◽

...

Keyword(s):

Second Line ◽

Second Line Therapy ◽

Comparative cost-effectiveness of cabozantinib as second-line therapy for patients with advanced hepatocellular carcinoma in Germany and the United States

BMC Gastroenterology ◽

10.1186/s12876-020-01241-y ◽

2020 ◽

Vol 20 (1) ◽

Author(s):

Maximilian Sieg ◽

Michael Hartmann ◽

Utz Settmacher ◽

Habibollah Arefian

Keyword(s):

United States ◽

Cost Effectiveness ◽

The United States ◽

Second Line ◽

Second Line Therapy ◽

Comparative Cost ◽

Hepatic reserve and the other conditions for regorafenib as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib in Japanese practical setting

Annals of Oncology ◽

10.1093/annonc/mdx660.047 ◽

2017 ◽

Vol 28 ◽

pp. x71

Author(s):

T. Terashima ◽

T. Yamashita ◽

K. Arai ◽

S. Kaneko

Keyword(s):

The Other ◽

Line Treatment ◽

Second Line ◽

First Line ◽

Hepatic Reserve ◽

First Line Therapy ◽

Pembrolizumab vs best supportive care for second-line advanced hepatocellular carcinoma: Randomized, phase 3 KEYNOTE-240 study

Annals of Oncology ◽

10.1093/annonc/mdw371.105 ◽

2016 ◽

Vol 27 ◽

pp. vi241 ◽

Cited By ~ 2

Author(s):

R. Finn ◽

S.L. Chan ◽

A.X. Zhu ◽

J. Knox ◽

A.-L. Cheng ◽

...

Keyword(s):

Supportive Care ◽

Best Supportive Care ◽

Second Line ◽

Phase 3

Role of regorafenib as second-line therapy and landscape of investigational treatment options in advanced hepatocellular carcinoma

Journal of Hepatocellular Carcinoma ◽

10.2147/jhc.s112537 ◽

2016 ◽

Vol Volume 3 ◽

pp. 31-36 ◽

Cited By ~ 22

Author(s):

Jörg Trojan ◽

Oliver Waidmann

Keyword(s):

Treatment Options ◽

Second Line ◽

Second Line Therapy ◽

Line Therapy ◽

Investigational Treatment

Phase III randomized study of second line ADI-peg 20 (A) plus best supportive care versus placebo (P) plus best supportive care in patients (pts) with advanced hepatocellular carcinoma (HCC).

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.15_suppl.4017 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. 4017-4017 ◽

Cited By ~ 14

Author(s):

Ghassan K. Abou-Alfa ◽

Shukui Qin ◽

Baek-Yeol Ryoo ◽

Sheng-Nan Lu ◽

Chia-Jui Yen ◽

...

Keyword(s):

Supportive Care ◽

Randomized Study ◽

Best Supportive Care ◽

Phase Iii ◽

Second Line